The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Adenosine Deaminase-Severe Combined Immunodeficiency Market?

The adenosine deaminase-severe combined immunodeficiency market size has experienced significant expansion in recent years. It is projected to expand from $5.94 billion in 2025 to $6.33 billion in 2026, maintaining a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historic period can be attributed to limited awareness of ada-scid, low availability of gene therapy solutions, reliance on supportive care treatments, lack of specialized treatment centers, and a high prevalence of treatment delays.

The adenosine deaminase-severe combined immunodeficiency market size is anticipated to experience substantial growth over the next few years. It is forecast to expand to $8.11 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.4%. This projected growth within the forecast period can be attributed to several factors, including advancements in autologous stem cell therapies, increased accessibility to enzyme replacement therapy, the expansion of specialized hospitals and clinics, higher rates of pediatric diagnosis, and greater healthcare funding for rare genetic disorders. Furthermore, major trends anticipated during this period involve a growing adoption of enzyme replacement therapies, the increasing development and access to gene therapy solutions, an uptick in stem cell transplantation procedures, the broadening of pediatric treatment programs for ADA-SCID, and an intensified focus on supportive care and patient monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21085&type=smp

Which Drivers Are Advancing The Adenosine Deaminase-Severe Combined Immunodeficiency Market Growth?

The increasing occurrence of genetic disorders is projected to fuel the expansion of the adenosine deaminase-severe combined immunodeficiency market moving forward. Genetic disorders are defined as medical conditions resulting from anomalies or mutations in an individual’s DNA, whether passed down or occurring without inheritance. The rising incidence of these disorders is attributed to elements such as enhanced diagnostic technologies, greater public awareness, advanced parental age, environmental influences, and demographic expansion. This growing prevalence of genetic disorders, particularly for conditions like adenosine deaminase-severe combined immunodeficiency (ADA-SCID), stimulates a greater demand for sophisticated diagnostic techniques and targeted treatment options. For instance, in October 2024, data from the Cystic Fibrosis Trust, a UK-based national charity, indicated that 11,148 people were living with cystic fibrosis (CF) in the UK in 2022, increasing to 11,318 in 2023. Therefore, the rising prevalence of genetic disorders is a key driver for the growth of the adenosine deaminase-severe combined immunodeficiency market.

Which Segment-Based Categories Are Covered In The Adenosine Deaminase-Severe Combined Immunodeficiency Market?

The adenosine deaminase-severe combined immunodeficiency market covered in this report is segmented –

1) By Treatment Type: Enzyme Replacement Therapy (ERT), Gene Therapy, Stem Cell Transplantation, Supportive Care Treatments

2) By Route of Administration: Intravenous, Subcutaneous

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Enzyme Replacement Therapy (ERT): Pegylated Adenosine Deaminase, Non-Pegylated Adenosine Deaminase

2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy

3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant

4) By Supportive Care Treatments: Antimicrobial Therapy, Immune System Support

Which Trends Are Shaping The Adenosine Deaminase-Severe Combined Immunodeficiency Market Landscape?

Leading organizations operating in the adenosine deaminase-severe combined immunodeficiency treatment market are focused on developing advanced solutions, such as direct gene therapy production, to improve patient access, lower treatment costs, and ensure a continuous supply. In-house gene therapy production describes the approach of generating autologous hematopoietic stem cells, which are genetically modified with a healthy ADA gene, within the organization’s own facilities, thereby lessening reliance on commercial manufacturers. For instance, in February 2025, the Fondazione Telethon, an Italy-based nonprofit biomedical research organization, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etuvetidigene autotemcel, a gene therapy initially developed for ADA-SCID and now also targeting Wiskott-Aldrich Syndrome. This therapy involves a single administration of autologous CD34+ stem and progenitor cells transduced with a lentiviral vector encoding the functional gene, having shown promising safety and efficacy outcomes in patients who received the treatment.

Which Key Players Are Active In The Adenosine Deaminase-Severe Combined Immunodeficiency Market?

Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Orchard Therapeutics PLC, Rocket Pharmaceuticals, Novartis AG, Bluebird Bio, Spark Therapeutics, Leadiant Biosciences, Sigma-Tau Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, Bristol-Myers Squibb, Roche Holding AG, Johnson & Johnson, AbbVie Inc, Gilead Sciences, CSL Limited, Bayer AG

Access The Complete Adenosine Deaminase-Severe Combined Immunodeficiency Market Report:

https://www.thebusinessresearchcompany.com/report/adenosine-deaminase-severe-combined-immunodeficiency-global-market-report

Which Region Is The Dominant Market In The Adenosine Deaminase-Severe Combined Immunodeficiency Market?

North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2025. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Adenosine Deaminase-Severe Combined Immunodeficiency Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21085&type=smp

Browse Through More Reports Similar to the Global Adenosine Deaminase-Severe Combined Immunodeficiency Market 2026, By The Business Research Company

Adeno Associated Viral Vectors Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Immunoassay Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Acne Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model